1. Pink Sheet

Latest EU Filings Include A First For BeiGene

AZ's Enhertu Has Also Been Filed

 
• By Neena Brizmohun

Potential treatments from BeiGene, AstraZeneca, Bayer and Cancer Prevention Pharmaceuticals are under review at the European Medicines Agency.

Hands
The EMA has started its review of several new drug marketing applications • Source: Shutterstock

BeiGene’s Brukinsa (zanubrutinib), a potential new therapy for a rare form of lymphoma, is one of four new products on the latest list of medicines under review at the European Medicines Agency.

Enhertu (trastuzumab deruxtecan), AstraZeneca PLC/Daiichi Sankyo’s advanced HER2-positive breast cancer treatment, is also among the four.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By Vibha Sharma

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 
• By Eliza Slawther

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.